Three earnings reports, one session, and a macro backdrop that has not made anyone's life easier. Chemed Corporation (CHE), Knowles (KN), and Texas Capital Bancshares (TCBI) all report Thursday — CHE and KN after the close, TCBI before the bell. Each is pricing in a different kind of expectation, and the dispersion between them is itself a signal to watch this morning.
Three Earnings, Three Divergent Setups: CHE, KN, TCBI
Chemed (CHE) enters Thursday's print in a structurally uncomfortable position. Last quarter, the company reported revenues of $639.3 million — flat year on year — and significantly missed both revenue and full-year EPS guidance estimates. This quarter, consensus expects revenue to again be flat year on year, a material slowdown from the 9.8% growth posted in the same quarter last year. Analysts have largely reconfirmed their estimates over the past 30 days, so the bar is neither being raised nor lowered. The current share price of $377.91 sits well below the average analyst price target of $443, a gap of roughly 17%, implying the market is factoring in execution risk. The broader healthcare providers segment has seen share prices rise 7.5% on average over the last month; CHE has gained only 1.2%. That relative underperformance suggests investors are discounting repeated delivery risk.
Knowles (KN) tells the opposite story. Last quarter the company posted revenues of $162.2 million, up 13.8% year on year, and beat on EPS and forward revenue guidance. Consensus now expects 11.5% year-on-year revenue growth for Q1, an uptick from flat revenue in the same quarter last year. The stock has surged 24.2% in the past month, currently priced at $31.42, almost exactly at the average analyst target of $31. Peers in the tech hardware sector, such as Jabil and TD SYNNEX, also posted strong results—Jabil with 23.1% revenue growth and a 6.8% beat, TD SYNNEX with 18.1% growth beating by 9.5%. The question for Knowles: with the share price already at target, is additional upside justifiable without a guidance upgrade?
Texas Capital Bancshares (TCBI) falls between the two. Last quarter it delivered revenues of $328.4 million, up 15.7% year on year, beating on both EPS and net interest income. The market expects 13.4% revenue growth this quarter, an improvement on the 9.4% growth in the prior-year quarter. The stock has gained 10.6% in the past month, outpacing the regional banks sector average of 8.8%. At a share price of $103.93 just under the analyst target of $104.31, TCBI is priced for fair value with high expectations around execution.
Macro Backdrop: Rates and Yield Curve Set the Stage
The yield environment is increasingly relevant as these companies report. The 10-year Treasury yield sits at 4.26% as of April 20, and the 2-year yield is at 3.72%, leaving the 10Y–2Y spread at as of April 21 — a level that is constructive for banks like TCBI but still limits significant expansion in net interest margins. The Federal Funds Effective Rate is 3.64%, with no major policy shifts indicated by recent Fed communications.
For Knowles and its sector peers, the level of interest rates continues to shape capital expenditure cycles at key clients, but recent hardware earnings suggest demand strength beyond just rate-driven effects.
Stocks365 Take: Divergence Signals Risk and Opportunity
The risk table is set with clear lines for each stock. For Texas Capital (TCBI), net interest income is in focus — the recent run-up in the stock came from outperformance on this line, and expectations are now high with the yield curve supportive. If NII beats again, the stock's momentum could continue; a miss likely creates asymmetric downside.
For Knowles (KN), the key is management guidance. With shares around analyst targets, forward-looking commentary and guidance will determine if the stock can maintain or build on recent gains. And for Chemed (CHE), any sign of revenue improvement above flat would signal a possible turn and could start closing the valuation gap to analyst targets.
What to Watch in These Thursday Earnings Prints
Thursday’s session will test recent price action in all three names. TCBI's print will show if recent performance was justified by fundamental delivery, especially on net interest income, given the current yield curve. Knowles’ release should reveal if management's forward guidance supports recent gains or sets up for mean reversion. For Chemed, the market is looking for any evidence of an inflection in operational delivery. By Friday morning, these three stocks may help clarify whether sector divergences can persist or if market consensus is about to narrow.